Want to see SLSN full AI Analyst Report?
SLSN Stock Chart & Stats
$2.17
--
Market closed
$2.17
--
Day’s Range― - ―
52-Week Range$0.61 - $4.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.43K
Market Cap
$66.39M
Enterprise Value$112.12M
Total Cash (Recent Filing)$573.00K
Total Debt (Recent Filing)$22.28M
Price to Earnings (P/E)61.4
Beta1.59
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding70,632,450
10 Day Avg. Volume39,901
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)6.38
Price to Sales (P/S)1.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap1.69
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda37.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Product TechnologiesIntroducing Chromalum and WHSPR provides durable product differentiation and opens adjacencies (e.g., hair/scalp care and SPF hybrids). Proprietary ingredients increase customer stickiness, support premium positioning, and can sustain higher gross margins if adoption by brand partners scales over months.
Sizable Shipped + Open Orders BookA $47M shipped + open orders backlog gives multi-month revenue visibility, supporting plant utilization and planned efficiency gains. That forward demand underpins execution of margin recovery and facility consolidation, making near-term revenue more predictable if OTIF stabilizes.
Improved Balance Sheet LeverageMaterial de-leveraging and a stronger equity base reduce solvency risk and increase financial flexibility. With lower relative debt, the company is better positioned to fund operational fixes and strategic investments over the next several months without immediate dependence on dilutive equity or emergency borrowing.
Bears Say
Weak And Volatile Free Cash FlowPersistent negative and volatile free cash flow undermines the firm's ability to fund operations, capex, and transformation initiatives internally. Over a 2–6 month horizon this raises refinancing and liquidity risk, potentially forcing costly external financing or delaying strategic investments.
Sharp Margin CompressionSignificant deterioration in net and EBITDA margins reduces earnings resilience and cash generation capacity. Even with recent gross margin improvement, the structural decline in profitability signals cost or mix pressures that could restrain durable margin recovery absent sustained operational gains.
Execution Risk From Operational ChangesOngoing process changes (SIOP, shift restructuring, consolidation) increase operational complexity and have already caused shipment delays. Execution lapses can prolong revenue shortfalls and inflate costs over coming months, making the path to targeted margins contingent on flawless implementation.
Solesence News
SLSN FAQ
What was Solesence’s price range in the past 12 months?
Solesence lowest stock price was $0.61 and its highest was $4.55 in the past 12 months.
What is Solesence’s market cap?
Solesence’s market cap is $66.39M.
When is Solesence’s upcoming earnings report date?
Solesence’s upcoming earnings report date is Aug 18, 2026 which is in 22 days.
How were Solesence’s earnings last quarter?
Currently, no data Available
Is Solesence overvalued?
According to Wall Street analysts Solesence’s price is currently Overvalued.
Does Solesence pay dividends?
Solesence does not currently pay dividends.
What is Solesence’s EPS estimate?
Solesence’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solesence have?
Solesence has 70,632,450 shares outstanding.
What happened to Solesence’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Solesence?
Currently, no hedge funds are holding shares in SLSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solesence Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.11%
Trailing 12-Months
Company Description
Solesence
Solesence, Inc., formerly known as Nanophase Technologies Corporation, specializes in the development and production of clean-label, inclusive, and mineral-based skincare and cosmetic products. The company collaborates with a diverse range of partners, from major global corporations to independent brands, employing its unique Active Stress Defense™ technology suite. Through this proprietary system, Solesence brings innovative beauty solutions to the market that provide effective environmental protection.
SLSN Company Deck
SLSN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: near-term financial results were pressured by shipment delays and investments tied to the Transform and Transcend initiative (revenue down ~11%, net loss and negative adjusted EBITDA), but key positives include a 300-basis-point gross margin improvement to 26%, a $47M shipped + open orders book, new proprietary technology launches (Chromalum and WHSPR), completed co-marketing activations with brand partners, and a clear operational roadmap (SIOP, shift changes, facility consolidation) with reiterated guidance including a 30% gross profit floor and a plan to return to double-digit EBITDA margins by year-end. Given the balance of material execution risks and encouraging operational and commercial progress, the tone is cautiously optimistic but transitional.View all SLSN earnings summariesTechnical Analysis
Ownership Overview
5.91% Insiders
2.03% Mutual Funds
<0.01% Other Institutional Investors
90.83% Public Companies and
Individual Investors